Healthcare Finance News September 2, 2024
J&J would become the ultimate arbiter of whether a rebate should be approved and paid, AHA says.
The American Hospital Association wants the Health Resources and Services Administration to levy monetary penalties against Johnson & Johnson if the drug company continues with its plan to give 340B hospitals rebates instead of upfront payments.
“If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take ‘immediate enforcement action,’ including assessing civil monetary penalties on Johnson & Johnson for intentionally overcharging 340B hospitals, th AHA said in a letter to the HRSA.
AHA’s General Counsel Chad...
Today's Sponsors
Today's Sponsor